- recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials
This clinical trial is studying an experimental medicine called briquilimab for adults with chronic hives (urticaria). It is an extension study for people who already took part in an earlier trial. Researchers want to see if the medicine is safe and works well when taken over a longer period.
Germany - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.
This study compares a new medicine (BP11) with an approved one (Xolair) for chronic hives that haven't responded to usual treatments. Researchers want to see if BP11 is safe and effective in reducing itching and other symptoms.
Hungary · Latvia · Bulgaria